Should You Join a Pharma or Medical Device Startup?

Balance scale with a glowing light bulb on one side and geometric blocks on the other

Every few months, someone at a big company gets a recruiter message. A small team is building a new drug-delivery system, a catheter, or a diagnostic that could change how we catch a disease. The pitch is exciting, the title is bigger, and there’s equity. Then the same person lies awake at 2 a.m. wondering if they’re about to make a mistake. Both reactions are reasonable. Here’s what I’d want you to know before you say yes or no.

I’ve had a lot of colleagues join small start-ups. Some were very happy with the streamlined work environment, but frankly, many others work a LOT of hours for people who aren’t qualified to lead. They may entice you with stock options, but unfortunately, many of those options can end up worthless. But…

The good parts are real

You’ll learn faster than you would anywhere else. At a large company, you might spend five years on one slice of one program. At a startup with fifteen people, the person who writes the regulatory strategy might also be the person who calls the contract manufacturer and fixes the slide deck an hour before the board meeting. It’s chaotic, but you pick up skills in months that might otherwise take a decade.

Your work is visible. When the team is small, nobody wonders what you do all day. If the pivotal study goes well, you know you helped. If a patient gets access to something that didn’t exist before, you can trace a line from your Tuesday afternoon to that outcome. For many people in this industry, that’s why they chose it.

The upside can be large. Early-stage equity can turn into serious money if the company gets acquired or goes public. It also comes with caveats, which we’ll get to.

You get a seat at the table. Startups need people who will make decisions, not just recommend them. If you’ve felt stuck behind layers of approval, that alone can feel like a breath of fresh air.

The hard parts are also real

Most of these companies fail. Roughly nine in ten drugs that enter clinical trials never reach approval. Devices have better odds, but a rejected submission or a missed funding round can end a company just as fast. A good scientist with a good idea can still lose to biology, timing, or a bad market.

One result can change everything. Your job might depend on a single data readout. When it’s good, the whole company celebrates. When it’s bad, layoffs sometimes come within weeks. Plenty of talented people have gone through this, and it isn’t a reflection on them. It’s just how the business works.

The money is less certain than it sounds. Stock options usually vest over four years, often with a one-year cliff, so if you leave or get laid off early, you may walk away with nothing. Each funding round dilutes your share. And if you leave, you often have about 90 days to buy your vested options, which can mean writing a large check for stock that might never be worth anything. Ask about all of this before you sign, not after.

The salary may be lower and the hours longer. Early-stage companies often pay below market and make up the difference in equity. You’ll also probably wear several hats, answer messages at odd hours, and cover for gaps in the team.

Regulated work leaves little room for improvisation. Startup culture loves moving fast. FDA expectations don’t bend to that. Documentation, quality systems, and validation still have to be done properly, and a team that cuts corners here can lose years. The best startups move fast within the rules. The worst ones forget the rules exist.

Questions worth asking before you say yes

You’re interviewing them as much as they’re interviewing you. Some questions I’d ask:

  1. How much runway do you have? Months of cash, not a vague “we’re well funded.”
  2. What’s the next milestone, and what happens if it doesn’t work? Listen to whether they have a real plan B.
  3. Who are the investors, and how do they behave when things get hard?
  4. What’s the exact equity offer? Number of shares, strike price, total shares outstanding, vesting schedule, and exercise window.
  5. Who will I report to, and how long have they been in the industry? Inexperienced leadership is a bigger risk than a risky molecule.
  6. How does the team talk about quality and compliance? Their tone will tell you a lot.

One questions that also needs to be answered is “who is funding the company?” Too many VC firms want a quick return, and your job may quickly shift from building a good business to making compromises and focusing on sales. I’ve seen this happen especially in medical affairs, where MSLs are asked to repeat sales pitches. I’ve also heard from legal people who were asked to risk their integrity and approve questionable marketing ads.

Size up the people running it

At a big company, you can work around a weak leader. At a startup with twenty people, the founders and executives decide whether you have a job in eighteen months. A brilliant molecule with shaky leadership is often a worse bet than a decent product with a team that has done this before.

Look at their track record, not just their résumé. Have they taken a product through FDA review before? Have they run a clinical trial, built a quality system, or managed a manufacturing transfer? A founder who is a gifted scientist but has never navigated a regulatory submission isn’t a bad person or a bad bet, but you should know whether they’ve surrounded themselves with people who have. First-time founders can absolutely succeed. The ones who do usually know what they don’t know and hire accordingly.

Ask how they talk about past failures. Nearly everyone in this industry has had a program fail or a company fold. The good leaders can tell you what went wrong, what they’d do differently, and what it cost the people around them. Those who blame the FDA, investors, or “bad luck” every time haven’t finished learning the lesson.

Watch how they handle bad news. Ask about a time a study missed its endpoint or a funding round fell through. Did they tell the team right away or sit on it for weeks? Leaders who hide bad news tend to hide it from you, too, and you’ll find out when the layoff email lands.

Check the turnover. Spend twenty minutes on LinkedIn. How long have the executives been there? Have the heads of regulatory, quality, or clinical turned over repeatedly? One departure is normal. A revolving door in the roles that keep a regulated company out of trouble is a warning sign.

Talk to people who’ve left. Current employees will be polite. Former employees will be more candid. Find a couple and ask them what the leadership was like under pressure, whether promises were kept, and whether they’d work for them again. Most people will answer if you’re respectful and specific.

Notice how they treat quality and compliance. Do leaders see the quality team as partners or as people slowing things down? If a founder jokes about “getting around” regulatory requirements, take that seriously. It tells you how decisions get made when no one is watching.

Pay attention to transparency. Do they share runway, milestones, and priorities with the whole team, or is everything on a need-to-know basis? Companies that are open about hard numbers tend to be more trustworthy about everything else.

Understand the board. A good board brings experience, pushes back, and helps in a crisis. A board that’s all investors and no operators, or one that rubber-stamps everything the CEO wants, offers less protection than it appears to.

A few red flags I’d treat seriously:

  • Vague or shifting answers about cash and runway
  • Timelines that sound too good to be true
  • A founder who makes every decision and doesn’t tolerate disagreement
  • Big claims with little data behind them
  • A team that seems afraid to ask questions in front of leadership

And a few good signs:

  • Leaders who say “I don’t know, let me find out”
  • Experienced people in the quality and regulatory seats, and leadership that listens to them
  • A culture where someone junior can raise a concern without it becoming a problem
  • Honest conversations about risk, even during the sales pitch

Trust your gut, too. If you leave the interview feeling like you were sold to rather than talked with, pay attention to that.

So, should you do it?

It depends on your situation more than on the company. A startup can be a great move if you have some financial cushion, can handle uncertainty, and want to grow quickly. It’s harder if you have a mortgage, kids, and no savings. That doesn’t mean you can’t do it. It just means the downside costs you more, so plan for it.

One way to think about it: take the most optimistic equity estimate and mentally set it to zero. If you’d still want the job for the learning, the mission, and the people, that’s a good sign. If the whole decision only makes sense when the stock becomes valuable, think again.

And if you decide to go, go in with your eyes open. Keep your network warm, save some of your salary, and remember that even a startup that doesn’t make it can leave you with skills and relationships that last your whole career.

Neither choice is wrong. People who regret it usually never looked closely at what they were signing up for.

About Richard Meyer

I’m Richard Meyer — a 25 year healthcare marketing strategist and writer focused on the intersection of direct-to-consumer marketing, healthcare economics, and human behavior.I started Work of DTC Marketing because too much of the conversation around pharma and healthcare marketing is either overly promotional, overly technical, or completely disconnected from how the system actually works.Here, I write about what DTC really does, how incentives drive behavior inside healthcare organizations, why patients are often treated like revenue streams instead of people, and why “best practices” are frequently just recycled assumptions.My background spans digital marketing, public relations, and healthcare strategy, and my approach is pragmatic, skeptical of hype, and grounded in data and lived experience. I’m less interested in what sounds good in a deck and more interested in what actually changes outcomes — for companies, doctors, and especially patients.

View all posts by Richard Meyer →

Leave a Reply